ID   DM424
AC   CVCL_F886
SY   Duke Melanoma 424
DR   GEO; GSM276745
DR   Wikidata; Q54831227
RX   PubMed=9241074;
RX   PubMed=19147755;
CC   From: Duke University Medical Center; Durham; USA.
CC   Omics: Transcriptomics; Microarray.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 10-04-25; Version: 11
//
RX   PubMed=9241074; DOI=10.1002/(SICI)1097-0142(19970801)80:3<401::AID-CNCR8>3.0.CO;2-U;
RA   Abdel-Wahab Z., Weltz C., Hester D., Pickett N., Vervaert C.,
RA   Barber J.R., Jolly D.J., Seigler H.F.;
RT   "A phase I clinical trial of immunotherapy with interferon-gamma
RT   gene-modified autologous melanoma cells: monitoring the humoral immune
RT   response.";
RL   Cancer 80:401-412(1997).
//
RX   PubMed=19147755; DOI=10.1158/1078-0432.CCR-08-1916;
RA   Augustine C.K., Yoo J.S., Potti A., Yoshimoto Y., Zipfel P.A.,
RA   Friedman H.S., Nevins J.R., Ali-Osman F., Tyler D.S.;
RT   "Genomic and molecular profiling predicts response to temozolomide in
RT   melanoma.";
RL   Clin. Cancer Res. 15:502-510(2009).
//